T Cell Vaccination in Patients With Progressive Multiple Sclerosis

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 31, 2002

Primary Completion Date

September 30, 2008

Study Completion Date

March 31, 2009

Conditions
Multiple Sclerosis
Interventions
BIOLOGICAL

multiple (4 autologous subcutaneous T cell vaccinations with T cell lines reactive to nine myelin peptides)

multiple (4 autologous subcutaneous T cell vaccinations with T cell lines reactive to nine myelin peptides at days 1, 30,90,180

BIOLOGICAL

T cell vaccination

Multiple injections of autologous T cell lines reactive to 9 myelin peptides.

Trial Locations (1)

91120

Dept of Neurology,Hadassah ein-Kerem, Jerusalem

All Listed Sponsors
lead

Hadassah Medical Organization

OTHER

NCT01448252 - T Cell Vaccination in Patients With Progressive Multiple Sclerosis | Biotech Hunter | Biotech Hunter